Nutritional supplements and extracts like Bloodroot have benefits and are used by cancer patients and those at-genetic risk of cancer. There is limited or hardly any clinical data available for use of nutritional supplements and foods in cancer patients. Generating clinical evidence of efficacy for cancer through a randomized clinical trial is further infeasible due to variations in genetics and cancer chemotherapy treatments across cancer patients. Hence a different and new approach is needed to find out for which cancers you should not take Bloodroot supplement and why should not take them?
Is it okay to take Bloodroot extracts or supplements for all cancer indications and any chemotherapy treatment? A common belief but a myth is that everything natural can only be of benefit and do no harm. For example, the use of grapefruit with certain medications is not recommended. Another example is the use of spinach with some blood thinning medications can cause adverse interactions and hence to be avoided. For cancer, nutrition including plant-based foods and supplements can influence outcomes and hence an extremely important decision which needs to be made. Hence NIH-National Cancer Institute has a website for nutrition for cancer care for patients which are generalized recommendations and not personalized for cancer indication and treatments.
A frequently asked question by cancer patients and those at-risk is “What Foods and Nutritional Supplements could be beneficial over others for me?”. “Who should not take an extract or supplement and why?”. Generic guidelines like eating only plant-based-foods or avoiding all sugar or adopting a keto diet is a good start but not actionable and personalized enough.
To find answers to questions on extracts and nutritional supplements and foods requires knowledge of contained active ingredients; genetic mutation prevalence for cancer indication; understanding of underlying cancer biology; chemotherapy treatments and mechanism of actions of active ingredients.
Taking Bloodroot extracts or nutritional supplements may benefit Primary Mucinous colorectal adenocarcinoma patients on Capecitabine treatment over Bitter Melon nutritional supplements. But Bloodroot supplements or Bloodroot extracts offer less benefit if on Radiation treatment for Primary Anaplastic Ependymoma compared to Cardamom. Similarly, taking nutritional supplements Bloodroot may benefit healthy individuals who are at genetic risk of cancer due to mutation of gene HRAS over Dandelion. But avoid nutritional supplements Bloodroot when at genetic risk of cancer due to mutation of gene CDKN2A.
The takeaway being – cancer, genomics, treatments and other personalized factors will influence decision making to questions like: Are extracts or nutritional supplements Bloodroot beneficial and should not be taken? Why should Bloodroot be not taken? Who should not take Bloodroot? What are side effects of Bloodroot with Radiation chemotherapy? What are the benefits of Bloodroot for cancer? Can Bloodroot help fight cancer and so on.
Whenever there are changes in chemotherapy treatments or cancer tissue genetics – the nutrition may change and hence needs to be re-evaluated. Do consider factors like cancer indication, ongoing chemotherapy treatments and nutritional supplements, age, gender, weight, height, lifestyle and genetics for personalization of nutrition.
Use of nutritional supplements – vitamins, herbs, minerals, probiotics, and other specialty categories are increasing. Supplements are high concentrations of active ingredients which are also found in different foods. Difference between supplements and foods being that foods contain more than one active ingredient at much lower concentrations. Every active ingredient in an extract or nutritional supplement or food has a unique mechanism of action which can influence nutrition decisions.
These are some example questions which nutrition planning should help answer for you. Should you take supplements Bloodroot? Should you take it when at genetic risk of cancer for mutation of gene HRAS? Should you take it when at genetic risk of cancer for mutation of gene CDKN2A? Should you take it when diagnosed with Primary Anaplastic Ependymoma? Should you take it when diagnosed with Primary Mucinous colorectal adenocarcinoma? Should you take it when on Capecitabine treatment? Should you continue taking it if you change your treatment from Capecitabine to Radiation? So a general explanation like – it is organic and plant-based or it increases immunity is not sufficient information for making a decision of use of Bloodroot extracts and nutritional supplements.
Genetic variations across cancer patients can be different and hence no two cancers are alike. The improved availability of “personalized to genetics” chemotherapy treatments and cancer disease monitoring via blood and saliva have been significant factors to improve outcomes. The earlier the lifestyle and treatment intervention – the better the influence on outcome. Genetic testing has the potential to assess cancer risk and susceptibility early. But for at-risk individuals besides regular monitoring in most cases there are no therapeutic treatment intervention options available. After diagnosis with cancer such as Primary Mucinous colorectal adenocarcinoma or Primary Anaplastic Ependymoma, the treatments get personalized to tumor genomics and factors like staging of disease, age and gender. During cancer remission (after treatment cycle is complete) – monitoring is used for assessment of any relapse and accordingly decide on next steps. A large majority of cancer patients and those at-risk may take nutritional supplements like Bloodroot.
So the question is that are all genetic risks and cancer indications to be considered uniformly when making decisions on the use of Bloodroot extracts or nutritional supplements? Are the biochemical pathway implications of genetic risk for cancer due to mutation of gene HRAS the same as due to mutation of gene CDKN2A? Are the implications of Primary Mucinous colorectal adenocarcinoma the same as Primary Anaplastic Ependymoma? Is it one and the same if you are on treatment with Radiation or Capecitabine?
Bloodroot – An Extract or Nutritional Supplement
Bloodroot or Sanguinaria canadensis is a herbaceous, perennial, flowering plant native to eastern part of North America.Because of the red latex/fluid of the rhizome of this plant, it is known as bloodroot. Bloodroot is considered to have medicinal properties due to its antioxidant, anti-inflammatory and anti-microbial effects. Native Americans have been using bloodroot as part of traditional medicine to treat a variety of health conditions including (Michael Z Wang et al, Dermatitis., Nov-Dec 2012) :
- Blood purification
- Pain and fever relief
- Wound healing
Bloodroot supplements contain many active ingredients including Sanguinarine at different concentration levels. The molecular pathways which are regulated by Bloodroot include Amino Acid Metabolism, Cell Cycle, Cell Cycle Checkpoints and Immune Evasion Signaling. These biochemical pathways directly or indirectly regulate specific cancer molecular endpoints like growth, spread and death of cancer cells. Because of this biological regulation – for cancer nutrition, the right choice of supplements like Bloodroot individually or in combination is an important decision to be made. When making decisions on the use of supplement Bloodroot over other nutritional supplements – do consider all these factors.
Who Should not take Bloodroot Supplements and Why?
There is no easy way to answer the question “For which cancers should I not chooseBloodroot nutritional supplements”. Just like the same chemotherapy treatment does not work across patients, for similar reasons Bloodroot in comparison with other nutritional supplements may be beneficial or not. Along with which cancer and associated genetics – the ongoing treatments, lifestyle habits, height, weight and food allergies are all factors in deciding if Bloodroot should be avoided or not and why.
1. Will Bloodroot Supplements benefit Primary Anaplastic Ependymoma patients undergoing Radiation treatment?
Primary Anaplastic Ependymoma is characterized and driven by specific genetic mutations like BRAF, CDC73 and CDKN2A leading to biochemical pathway changes in RAS-RAF Signaling, MAPK Signaling, Cell Cycle Checkpoints and Cell Cycle. A cancer treatment like Radiation works through a specific pathway mechanism of action. The goal is to have a good overlap between the treatment and cancer driving pathways for a personalized approach which is effective. In such a condition any food or nutritional supplement which has a contrary effect to the treatment or reduces the overlap should be avoided. As an example, Bloodroot supplement should not be taken for Primary Anaplastic Ependymoma along with treatment Radiation. Bloodroot supplement impacts the biochemical pathway called Cell Cycle which either promotes drivers of the disease and/or nullifies the treatment effect. Some of the factors which should be considered when choosing nutrition are type of cancer, treatments and supplements being taken currently (if any
2. Will Bloodroot Supplements benefit Primary Mucinous colorectal adenocarcinoma Patients undergoing Capecitabine Treatment?
Primary Mucinous colorectal adenocarcinoma is characterized and driven by specific genetic mutations like TTN, APC and KRAS leading to biochemical pathway changes in Amino Acid Metabolism, Angiogenesis, G-protein-coupled Receptor Signaling and Growth Factor Signaling. A cancer treatment like Capecitabine works through specific pathway mechanisms. The goal is to have a good overlap between the treatment and cancer driving pathways for a personalized approach. In such a condition any food or nutritional supplement which supports treatment action or improves the overlap should be considered. As an example, Bloodroot supplements should be considered for Primary Mucinous colorectal adenocarcinoma along with the treatment Capecitabine. Bloodroot supplement impacts pathways/processes like Amino Acid Metabolism which either obstruct drivers of Primary Mucinous colorectal adenocarcinoma and/or improve Capecitabine treatment effect.
Foods to Eat After Cancer Diagnosis!
No two cancers are the same. Go beyond the common nutrition guidelines for everyone and make personalized decisions about food and supplements with confidence.
3. What about Bloodroot Supplements for Healthy Individuals with CDKN2A Mutation associated Genetic Risk?
Different companies offer panels of genes to be tested for assessing genetic risk to different cancers. These panels cover genes associated with cancers of the breast, ovary, uterus, prostate, and gastrointestinal system and others. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant may also guide testing and diagnosis of at-risk relatives. CDKN2A is one of the genes generally available in panels for cancer risk testing.
CDKN2A mutation causes biochemical pathways/processes like Cell Cycle Checkpoints and Cell Cycle to get impacted. These pathways are direct or indirect drivers of cancer molecular endpoints. Bloodroot should not be taken when the genetic panel identifies mutation of CDKN2A for Skin Cancer. Bloodroot impacts pathways/processes like Cell Cycle Checkpoints and creates adverse conditions with CDKN2A.
4. What about Bloodroot Supplements for Healthy Individuals with HRAS Mutation associated Genetic Risk?
HRAS is one of the genes available in panels for cancer risk testing. HRAS mutation causes biochemical pathways/processes like Immune Evasion Signaling and RAS-RAF Signaling to get impacted. These pathways are direct or indirect drivers of cancer molecular endpoints. Bloodroot supplements may be considered when the genetic panel identifies mutations in HRAS for Pheochromocytoma And Paraganglioma. Bloodroot impacts pathways/processes like Immune Evasion Signaling and creates a canceling effect in those individuals with HRAS mutation.
* Other Factors are also included like BMI, Treatments, Lifestyle Habits
It is important to remember that cancer chemotherapy treatments and nutrition are never the same for everyone. Food and nutritional supplements like Bloodroot are chosen by you and can influence outcomes.
“What should I eat?” is a commonly asked question by cancer patients and those at-risk. The answer to this question depends on cancer indication, underlying genetics, current chemotherapy treatments, food allergies, lifestyle information, and food preferences.
The addon.life approach to nutrition personalization uses knowledge of active ingredients contained in foods and nutritional supplements, cancer biology, chemotherapy treatment action and genetic mutation prevalence across cancer indications. addon.life team of clinicians, clinical scientists and engineers are experts in cancer biology focusing only on nutrition personalization for cancer patients and those at-risk.
What food you eat and which supplements you take is a decision you make. Your decision should include consideration of the cancer gene mutations, which cancer, ongoing treatments and supplements, any allergies, lifestyle information, weight, height and habits.
The nutrition planning for cancer from addon is not based on internet searches. It automates the decision making for you based on molecular science implemented by our scientists and software engineers. Irrespective of whether you care to understand the underlying biochemical molecular pathways or not - for nutrition planning for cancer that understanding is needed.
Get started NOW with your nutrition planning by answering questions on the name of cancer, genetic mutations, ongoing treatments and supplements, any allergies, habits, lifestyle, age group and gender.
- cBioPortal for Cancer Genomics
- Bis(4-hydroxy-2H-chromen-2-one): synthesis and effects on leukemic cell lines proliferation and NF-κB regulation.
- FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death.
- Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer.
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
- The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells.
- cBioPortal for Cancer Genomics
Personalized Nutrition for Cancer!
Cancer changes with time. Customize and modify your nutrition based on cancer indication, treatments, lifestyle, food preferences, allergies and other factors.